LXEO Stock Summary and Trading Ideas (Lexeo Therapeutics | NASDAQ:LXEO)

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Lexeo Therapeutics trades on the NASDAQ stock market under the symbol LXEO.

As of September 9, 2026, LXEO stock price declined to $4.48 with 295,132 million shares trading.

LXEO has a beta of 2.12, meaning it tends to be more sensitive to market movements. LXEO has a correlation of 0.11 to the broad based SPY ETF.

LXEO has a market cap of $367.57 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that LXEO belongs to (by Net Assets): XBI, VTI, VXF, KOMP, VTWO.

LXEO has underperformed the market in the last year with a price return of -14.7% while the SPY ETF gained +18.7%. However, in the short term, LXEO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.4% vs +3.4% return in SPY. But in the last 2 weeks, LXEO shares have been beat by the market, returning -12.7% compared to an SPY return of -0.5%.

LXEO support price is $4.59 and resistance is $4.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXEO shares will trade within this expected range on the day.